FDA committee recommends AstraZeneca and Sanofi’s RSV prophylactic nirsevimab
The committee overwhelmingly supported nirsevimab’s risk-benefit profile in both newborns and infants entering their first RSV season.
Baudax Bio reports promising additional data for neuromuscular blockade agent
AstraZeneca ends Phase IV Andexxa trial after positive results
ASCO 2023: Janssen’s Carvykti wins in earlier treatment of multiple myeloma
ASCO 2023: Moderna and MSD’s vaccine/IO combo reduces chances of melanoma spreading
ASCO 2023: Ellipses Pharma advances plans for RET inhibitor following encouraging results
Analysis
View More
Subscribe to our Newsletter
Get industry leading news, data and analysis delivered to your inbox
Themes
View MoreChina grants EUA to Covid-19 vaccine against XBB descendent lineages
The vaccine has been developed by WestVac Biopharma along with the West China Medical Center and Sichuan University.
More themes
Insights
View MoreWho’s hiring who? Hiring activity in the Asia-Pacific pharma industry increased by 2% in Q1 2023
The Asia-Pacific pharma industry experienced a 2% rise in new job postings in Q1 2023 compared with the previous quarter,…
Oragenics secures CQDM funding for Covid-19 vaccine antigen development
Revised EU/Pfizer/BioNTech Covid-19 vaccine deal may lead to a Comirnaty monopoly
XtalPi announces $250m AI drug discovery collaboration with Eli Lilly
University of Sydney will use AI to boost cancer drug research